PTH and Marchiafava-Bignami disease: The multivariate-adjusted logistic regression analysis showed that, of all the medications examined, only VDRA use (OR 0.512, 95% CI 0.347–0.738, P = 0.0003) was independently associated with a significantly reduced risk of dialysis-requiring uremic nausea, adjusted by chronic kidney disease-mineral and bone disorder (CKD-MBD)-associated factors, such as corrected calcium, phosphorus, intact PTH, CaCO3 (medication), and nephrologist follow-up period.